InsiderSource
TARS

Tarsus Pharmaceuticals, Inc.

SEC CIK 1819790
$61.95 −2.5% · 90 days
90-day buys
$0
0 open-market
90-day sells
$7.3M
25 open-market
Net insider flow
−$7.3M
Net selling
Filings shown
34
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at TARS have sold a net $7.3M of stock (0 open-market buys vs 25 sells).

Largest recent trade: Azamian Bobak R. sold $801.6K of TARS, trimming their stake 20%.

Most active filer: Neervannan Seshadri, with 6 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for TARS, newest first
View on SEC EDGAR ↗
TARS
Tarsus Pharmaceuticals, Inc.
Sell Neervannan Seshadri · Chief Operating Officer · Open-market sale · filed Mar 24, 2026 ΔOwn −3.5%

Neervannan Seshadri sold $199.5K of TARS, trimming their stake 3%.

−$199.5K
2,989 sh @ $67
TARS
Tarsus Pharmaceuticals, Inc.
Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −11%

Whitfield Dianne C. sold $279.7K of TARS, trimming their stake 11%.

−$279.7K
4,174 sh @ $67
TARS
Tarsus Pharmaceuticals, Inc.
Sell Wahl Bryan · General Counsel · Open-market sale · filed Mar 19, 2026 ΔOwn −6.2%

Wahl Bryan sold $283.5K of TARS, trimming their stake 6%.

−$283.5K
4,231 sh @ $67
TARS
Tarsus Pharmaceuticals, Inc.
Sell Neervannan Seshadri · Chief Operating Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −5.1%

Neervannan Seshadri sold $307.5K of TARS, trimming their stake 5%.

−$307.5K
4,589 sh @ $67
Advertisement
TARS
Tarsus Pharmaceuticals, Inc.
Sell Mottiwala Aziz · Chief Commercial Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −6.7%

Mottiwala Aziz sold $297.5K of TARS, trimming their stake 7%.

−$297.5K
4,440 sh @ $67
TARS
Tarsus Pharmaceuticals, Inc.
Sell Lin Elizabeth Yeu · Chief Medical Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −1.6%

Lin Elizabeth Yeu sold $26.1K of TARS, trimming their stake 2%.

−$26.1K
390 sh @ $67
TARS
Tarsus Pharmaceuticals, Inc.
Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 19, 2026 ΔOwn −26%

Azamian Bobak R. sold $801.6K of TARS, trimming their stake 26%.

−$801.6K
11,964 sh @ $67
TARS
Tarsus Pharmaceuticals, Inc.
Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −9.4%

Whitfield Dianne C. sold $279.7K of TARS, trimming their stake 9%.

−$279.7K
4,071 sh @ $69
TARS
Tarsus Pharmaceuticals, Inc.
Sell Wahl Bryan · General Counsel · Open-market sale · filed Mar 19, 2026 ΔOwn −5.7%

Wahl Bryan sold $283.4K of TARS, trimming their stake 6%.

−$283.4K
4,125 sh @ $69
TARS
Tarsus Pharmaceuticals, Inc.
Sell Mottiwala Aziz · Chief Commercial Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −6.2%

Mottiwala Aziz sold $297.5K of TARS, trimming their stake 6%.

−$297.5K
4,330 sh @ $69
TARS
Tarsus Pharmaceuticals, Inc.
Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 19, 2026 ΔOwn −20%

Azamian Bobak R. sold $801.6K of TARS, trimming their stake 20%.

−$801.6K
11,667 sh @ $69
TARS
Tarsus Pharmaceuticals, Inc.
Sell Whitfield Dianne C. · Chief Human Resources Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −8.5%

Whitfield Dianne C. sold $279.7K of TARS, trimming their stake 9%.

−$279.7K
4,029 sh @ $69
TARS
Tarsus Pharmaceuticals, Inc.
Sell Wahl Bryan · General Counsel · Open-market sale · filed Mar 19, 2026 ΔOwn −5.3%

Wahl Bryan sold $283.5K of TARS, trimming their stake 5%.

−$283.5K
4,084 sh @ $69
TARS
Tarsus Pharmaceuticals, Inc.
Sell Neervannan Seshadri · Chief Operating Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −3.2%

Neervannan Seshadri sold $216.9K of TARS, trimming their stake 3%.

−$216.9K
3,125 sh @ $69
TARS
Tarsus Pharmaceuticals, Inc.
Sell Mottiwala Aziz · Chief Commercial Officer · Open-market sale · filed Mar 19, 2026 ΔOwn −5.8%

Mottiwala Aziz sold $297.5K of TARS, trimming their stake 6%.

−$297.5K
4,286 sh @ $69
TARS
Tarsus Pharmaceuticals, Inc.
Sell Azamian Bobak R. · Director, President/CEO and Board Chair · Open-market sale · filed Mar 19, 2026 ΔOwn −16%

Azamian Bobak R. sold $761.7K of TARS, trimming their stake 16%.

−$761.7K
10,972 sh @ $69
Advertisement

About TARS insider activity

This page tracks every recent Form 4 filed for Tarsus Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is TARS insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Tarsus Pharmaceuticals, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.